Disorders Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Disorders stocks.

Disorders Stocks Recent News

Date Stock Title
May 10 OMER Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
May 10 REGN Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past week
May 10 REGN Q1 2024 Intellia Therapeutics Inc Earnings Call
May 9 CPRX HHS panel to vote in Nov. on DMD screening for newborns
May 9 CPRX Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript
May 9 PHAT Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
May 9 OMER Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
May 9 PHAT Phathom Pharmaceuticals Non-GAAP EPS of -$1.11 beats by $0.06, revenue of $1.91M misses by $0.23M
May 9 PHAT Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 9 FULC Fulcrum Therapeutics to Participate in Upcoming May Conferences
May 9 ITCI Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its First-Quarter Earnings: Here's What Analysts Think
May 9 IONS The Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 9 REGN Regeneron’s gene therapy triumphs twice, restoring hearing in children
May 8 CPRX Catalyst Pharmaceuticals Non-GAAP EPS of $0.38 beats by $0.08, revenue of $98.44M misses by $0.33M
May 8 CPRX Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
May 8 ITCI Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call Transcript
May 8 IONS Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript
May 8 IONS Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
May 8 REGN Regeneron gene therapy improves hearing in child deafness
May 8 FULC Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
Disorders

Disorder may refer to randomness, non-order, or no intelligible pattern. Disorder may also refer to:

Browse All Tags